Evaluation of Compliance With Treatment by Elvitegravir/Cobicistat/FTC/Tenofovir Alafenamide (E/C/F/TAF) in HIV Post-exposure Prophylaxis (to Infected Blood or Sexual Contact)
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 13 Feb 2018 Planned End Date changed from 1 Oct 2017 to 31 Jul 2018.
- 13 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 31 Mar 2018.
- 13 Feb 2018 Status changed from not yet recruiting to recruiting.